Verona, Italy

Michela Beltrani

USPTO Granted Patents = 2 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michela Beltrani: Innovator in Heterocyclic Compounds

Introduction

Michela Beltrani is a prominent inventor based in Verona, Italy. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit Delta-5 Desaturase. With a total of two patents to her name, her work is paving the way for advancements in treating metabolic and cardiovascular disorders.

Latest Patents

Michela's latest patents include innovative methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors. The first patent details compounds that are useful for the inhibition of Delta-5 Desaturase (D5D), providing a general Formula I where the variables are defined. This disclosure also includes pharmaceutical compositions comprising these compounds, along with their uses in treating various disorders. The second patent reiterates the same focus on heterocyclic compounds as Delta-5 Desaturase inhibitors, emphasizing their potential in pharmaceutical applications.

Career Highlights

Michela is currently employed at Amgen Inc., a leading biotechnology company. Her work at Amgen has allowed her to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Some of her notable coworkers include Teodora P Damyanova and Iain Lingard. Their collaborative efforts have further enhanced the research and development of innovative pharmaceutical solutions.

Conclusion

Michela Beltrani's contributions to the field of pharmaceutical sciences through her patents on Delta-5 Desaturase inhibitors highlight her role as an influential inventor. Her work continues to inspire advancements in medical treatments and showcases the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…